The estimated Net Worth of Robert Andrew Berman is at least $455 mil dollars as of 18 May 2021. Mr Berman owns over 3,000 units of Hancock Jaffe Laboratories Inc stock worth over $38,780 and over the last 9 years he sold HJLI stock worth over $0. In addition, he makes $415,808 as CEO & Director at Hancock Jaffe Laboratories Inc.
Sign up
Mr Berman HJLI stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Hancock Jaffe Laboratories Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of HJLI stock worth $16,410 on 18 May 2021.
The largest trade he's ever made was buying 21,740 units of Hancock Jaffe Laboratories Inc stock on 12 March 2019 worth over $25,001. On average, Mr trades about 3,860 units every 161 days since 2016. As of 18 May 2021 he still owns at least 3,736 units of Hancock Jaffe Laboratories Inc stock.
You can see the complete history of Mr Berman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Robert A. Berman biography
Robert A. Berman is the CEO & Director at Hancock Jaffe Laboratories Inc.
What is the salary of Mr Berman?
As the CEO & Director of Hancock Jaffe Laboratories Inc, the total compensation of Mr Berman at Hancock Jaffe Laboratories Inc is $415,808. There are no executives at Hancock Jaffe Laboratories Inc getting paid more.
How old is Mr Berman?
Mr Berman is 57, he's been the CEO & Director of Hancock Jaffe Laboratories Inc since . There are 3 older and no younger executives at Hancock Jaffe Laboratories Inc. The oldest executive at Hancock Jaffe Laboratories Inc is Dr. Marc H. Glickman, 71, who is the Sr. VP & Chief Medical Officer.
What's Mr Berman's mailing address?
Robert's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Insiders trading at Hancock Jaffe Laboratories Inc
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman, eFrancis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
What does Hancock Jaffe Laboratories Inc do?
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
What does Hancock Jaffe Laboratories Inc's logo look like?
Complete history of Mr Berman stock trades at Hancock Jaffe Laboratories Inc
Hancock Jaffe Laboratories Inc executives and stock owners
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include:
-
Robert A. Berman,
CEO & Director -
Dr. Marc H. Glickman,
Sr. VP & Chief Medical Officer -
Craig Thomas Glynn,
CFO & Treasurer -
Dr. Benedict Broennimann M.D.,
Chief Medical Officer of Outside of United States -
Warren Hancock,
Co-founder -
Marc H. Glickman,
SVP & Chief Medical Officer -
Marcus W. Robins,
Director -
Sanjay Shrivastava,
Director -
Benedict Broennimann,
Chief Medical Officer, OUS -
Francis Duhay,
Director -
Holding, S.A. Biodyne,
-
Robert Gray,
Director -
Matthew Jenusaitis,
Director -
Craig Glynn,
Chief Financial Officer